These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 9084574)

  • 1. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers.
    Stichtenoth DO; Wagner B; Frölich JC
    J Investig Med; 1997 Feb; 45(2):44-9. PubMed ID: 9084574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of selective inhibition of the inducible cyclooxygenase on renin release in healthy volunteers.
    Stichtenoth DO; Wagner B; Frölich JC
    J Investig Med; 1998 Aug; 46(6):290-6. PubMed ID: 9737091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meloxicam, 15 mg/day, spares platelet function in healthy volunteers.
    de Meijer A; Vollaard H; de Metz M; Verbruggen B; Thomas C; Novakova I
    Clin Pharmacol Ther; 1999 Oct; 66(4):425-30. PubMed ID: 10546927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers.
    van Kraaij DJ; Hovestad-Witterland AH; de Metz M; Vollaard EJ
    Br J Clin Pharmacol; 2002 Jun; 53(6):644-7. PubMed ID: 12047490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects.
    Panara MR; Renda G; Sciulli MG; Santini G; Di Giamberardino M; Rotondo MT; Tacconelli S; Seta F; Patrono C; Patrignani P
    J Pharmacol Exp Ther; 1999 Jul; 290(1):276-80. PubMed ID: 10381787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings.
    Engelhardt G; Bögel R; Schnitzler C; Utzmann R
    Biochem Pharmacol; 1996 Jan; 51(1):29-38. PubMed ID: 8534265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.
    Van Hecken A; Schwartz JI; Depré M; De Lepeleire I; Dallob A; Tanaka W; Wynants K; Buntinx A; Arnout J; Wong PH; Ebel DL; Gertz BJ; De Schepper PJ
    J Clin Pharmacol; 2000 Oct; 40(10):1109-20. PubMed ID: 11028250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4'-isomer.
    Pairet M; van Ryn J; Schierok H; Mauz A; Trummlitz G; Engelhardt G
    Inflamm Res; 1998 Jun; 47(6):270-6. PubMed ID: 9683035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of meloxicam on platelet function in healthy adults: a randomized, double-blind, placebo-controlled trial.
    Rinder HM; Tracey JB; Souhrada M; Wang C; Gagnier RP; Wood CC
    J Clin Pharmacol; 2002 Aug; 42(8):881-6. PubMed ID: 12162470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers.
    Van Ryn J; Kink-Eiband M; Kuritsch I; Feifel U; Hanft G; Wallenstein G; Trummlitz G; Pairet M
    J Clin Pharmacol; 2004 Jul; 44(7):777-84. PubMed ID: 15199082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo effects of meloxicam and aspirin on blood, gastric mucosal, and synovial fluid prostanoid synthesis in dogs.
    Jones CJ; Streppa HK; Harmon BG; Budsberg SC
    Am J Vet Res; 2002 Nov; 63(11):1527-31. PubMed ID: 12428662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the induction of nitric oxide synthase and cyclo-oxygenase in rat aorta in organ culture.
    Bishop-Bailey D; Larkin SW; Warner TD; Chen G; Mitchell JA
    Br J Pharmacol; 1997 May; 121(1):125-33. PubMed ID: 9146896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers.
    Stichtenoth DO; Marhauer V; Tsikas D; Gutzki FM; Frölich JC
    Kidney Int; 2005 Nov; 68(5):2197-207. PubMed ID: 16221219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1.
    Ogino K; Hatanaka K; Kawamura M; Katori M; Harada Y
    Pharmacology; 1997 Jul; 55(1):44-53. PubMed ID: 9309800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ketoprofen and ibuprofen on platelet aggregation and prostanoid formation in man.
    Stichtenoth DO; Tsikas D; Gutzki FM; Frölich JC
    Eur J Clin Pharmacol; 1996; 51(3-4):231-4. PubMed ID: 9010690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meloxicam inhibits prostaglandin E(2) generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach.
    Ogino K; Hatanaka K; Kawamura M; Ohno T; Harada Y
    Pharmacology; 2000 Nov; 61(4):244-50. PubMed ID: 11093076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use.
    Blain H; Boileau C; Lapicque F; Nédélec E; Loeuille D; Guillaume C; Gaucher A; Jeandel C; Netter P; Jouzeau JY
    Br J Clin Pharmacol; 2002 Mar; 53(3):255-65. PubMed ID: 11874389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of meloxicam, indomethacin or NS-398 on eicosanoid synthesis by fresh human gastric mucosa.
    Tavares IA
    Aliment Pharmacol Ther; 2000 Jun; 14(6):795-9. PubMed ID: 10848664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferential inhibition of cyclooxygenase-2 by meloxicam in human rheumatoid synoviocytes.
    Tsubouchi Y; Sano H; Yamada R; Hashiramoto A; Kohno M; Kusaka Y; Kondo M
    Eur J Pharmacol; 2000 May; 395(3):255-63. PubMed ID: 10812057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.